<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-158117" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nonorganic Vision Loss</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Manion</surname>
            <given-names>Garrett N.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Stokkermans</surname>
            <given-names>Thomas J.</given-names>
          </name>
          <aff>University Hospitals of Cleveland</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Garrett Manion declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Thomas Stokkermans declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-158117.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Nonorganic vision loss (NOVL), also known as functional, psychogenic, or hysterical vision loss, is a unique subset of visual impairment characterized by a disparity between the patient's self-reported visual symptoms and clinical findings. NOVL represents a broad spectrum of conditions where an individual presents with visual dysfunction that any identifiable organic pathology cannot fully explain.<xref ref-type="bibr" rid="article-158117.r1">[1]</xref></p>
        <p>The understanding of NOVL is intrinsically connected to the knowledge of the visual pathway, a complex network comprising the ocular structures (cornea, crystalline lens, and retina), the optic nerves, chiasm, and tracts, the lateral geniculate bodies of the thalamus, and the visual cortex of the occipital lobe.<xref ref-type="bibr" rid="article-158117.r2">[2]</xref> A detailed clinical assessment of this pathway is crucial to exclude organic causes of vision loss, such as ocular diseases, neurological conditions, or systemic diseases.<xref ref-type="bibr" rid="article-158117.r3">[3]</xref></p>
        <p>NOVL is not always a case of malingering or conscious feigning of symptoms&#x000a0;and&#x000a0;usually occurs without the patient's awareness of the nonorganic nature of the disease.<xref ref-type="bibr" rid="article-158117.r4">[4]</xref>&#x000a0;The natural history and pattern of the spread of NOVL vary among individuals. NOVL may affect visual acuity, visual fields, or color vision and may present in various patterns, from monocular to binocular involvement. Some individuals may experience sudden vision loss, while others report a progressive decline.<xref ref-type="bibr" rid="article-158117.r3">[3]</xref><xref ref-type="bibr" rid="article-158117.r5">[5]</xref>&#x000a0;NOVL can profoundly affect the quality of life and activities of daily living, highlighting the need for prompt recognition and appropriate management.<xref ref-type="bibr" rid="article-158117.r6">[6]</xref>&#x000a0;</p>
        <p>Understanding the etiology and pathophysiology of NOVL requires a biopsychosocial approach that acknowledges the interaction of physiological, psychological, and social contributing factors. The early identification of NOVL and appropriate intervention can significantly improve patient outcomes and mitigate the impact on healthcare resources. NOVL may be the only sign of psychological distress, and questions during the eye exam regarding suicidal ideation may save lives.<xref ref-type="bibr" rid="article-158117.r7">[7]</xref>&#x000a0;</p>
        <p>Healthcare providers should recognize that when an organic etiology for vision loss has been ruled out, malingering&#x000a0;is usually correlated with avoidance of extensive investigation, while people unconsciously suffering from NOVL, as well as those with factitious disorder, will actively seek out additional investigations to determine the cause of the vision loss.<xref ref-type="bibr" rid="article-158117.r8">[8]</xref><xref ref-type="bibr" rid="article-158117.r9">[9]</xref>&#x000a0;NOVL remains an underrecognized and underresearched area in ophthalmology. This activity reviews&#x000a0;the current understanding of NOVL, its various manifestations, and approaches to evaluation and management to equip healthcare professionals with the knowledge and tools necessary to address this complex condition.</p>
      </sec>
      <sec id="article-158117.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of&#x000a0;NOVL is multifactorial and includes physiological, psychological, and social factors. Unlike organic visual impairments where an identifiable pathologic condition of the eye or visual pathway is present, NOVL arises absent observable pathologies.<xref ref-type="bibr" rid="article-158117.r1">[1]</xref></p>
        <p>Psychogenic factors are important causes of NOVL. In some patients, vision loss may&#x000a0;be a form of conversion disorder, where psychological distress is converted into physical symptoms.&#x000a0;Patients with a history of anxiety, depression, posttraumatic stress disorder, or other psychiatric conditions may be more prone to NOVL. NOVL can also occur as a form of symptom amplification when an individual unconsciously exaggerates minor or nonspecific visual disturbances due to heightened health concerns.<xref ref-type="bibr" rid="article-158117.r10">[10]</xref>&#x000a0;Symptom amplification is most frequently&#x000a0;observed in individuals with health anxiety or who have recently been diagnosed with an ocular condition; concerns about potential vision loss lead to an overemphasis on subjective visual symptoms.<xref ref-type="bibr" rid="article-158117.r11">[11]</xref>&#x000a0;NOVL may also present as part of factitious disorder or malingering, where the patient consciously feigns visual symptoms for secondary gain, such as seeking attention, evading responsibilities, or obtaining disability benefits.<xref ref-type="bibr" rid="article-158117.r12">[12]</xref>&#x000a0;However, these etiologies should be considered only after other potential causes have been thoroughly excluded.<xref ref-type="bibr" rid="article-158117.r4">[4]</xref></p>
        <p>Some cases of NOVL are linked to a history of trauma or abuse; the visual symptoms represent a physical manifestation of the psychological impact of these experiences.<xref ref-type="bibr" rid="article-158117.r13">[13]</xref>&#x000a0;In children and adolescents, NOVL may be associated with school or family stressors.<xref ref-type="bibr" rid="article-158117.r14">[14]</xref> Social and cultural factors may also influence the occurrence of NOVL.; individuals facing significant life stressors, with limited social support networks, or socioeconomically disadvantaged situations may be more susceptible to developing NOVL.<xref ref-type="bibr" rid="article-158117.r13">[13]</xref></p>
        <p>In the <italic toggle="yes">Diagnostic and Statistical Manual of Mental Disorders</italic>, Fifth Edition (<italic toggle="yes">DSM-5</italic>), functional vision loss falls under the category of "Somatic Symptom and Related Disorders," specifically under the diagnosis of "Conversion Disorder (Functional Neurological Symptom Disorder)." The&#x000a0;<italic toggle="yes">DSM-5</italic> defines&#x000a0;Conversion Disorder as one or more symptoms of altered voluntary motor or sensory function that are found, after appropriate medical assessment, to be incompatible with recognized neurological or medical conditions.<xref ref-type="bibr" rid="article-158117.r3">[3]</xref></p>
      </sec>
      <sec id="article-158117.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The frequency of NOVL varies among settings and studied populations. A randomized trial of 127 adult patients with convergence disorder demonstrated that 16% possessed functional visual symptoms.<xref ref-type="bibr" rid="article-158117.r6">[6]</xref>&#x000a0;</p>
        <p>A pediatric ophthalmology department in Belgium reported that from 2007 to 2014, 50% of children presenting with 'vision loss' were diagnosed with NOVL; the average age at diagnosis was 11 years, with a female predominance. Approximately 88% of affected children recovered within 2 weeks; the recurrence rate was 12.9%. Additionally, 25% of the children with NOVL required child psychiatric treatment.<xref ref-type="bibr" rid="article-158117.r14">[14]</xref>&#x000a0;Symptoms included blurred vision, diplopia, nystagmus, visual field deficits, and complete blindness.</p>
        <p>While NOVL occurs in all age groups and sexes, some studies have suggested a slightly higher prevalence in women and adolescents.<xref ref-type="bibr" rid="article-158117.r13">[13]</xref><xref ref-type="bibr" rid="article-158117.r14">[14]</xref> The worldwide incidence and prevalence rates are poorly established due to varying reporting and diagnostic criteria. However, NOVL remains a notable contributor to visual impairment, given its significant psychosocial implications and impact on healthcare resources.</p>
      </sec>
      <sec id="article-158117.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>NOVL&#x000a0;is a disorder of perception, as opposed to a structural or functional abnormality within the visual system. The pathogenic mechanisms of NOVL are poorly understood but likely involve psychological and neurophysiological processes.<xref ref-type="bibr" rid="article-158117.r15">[15]</xref>&#x000a0;Despite the lack of knowledge about the pathophysiologic processes of NOVL, the disease process is very real for the patient.<xref ref-type="bibr" rid="article-158117.r3">[3]</xref></p>
        <p>NOVL is often associated with psychological conditions like anxiety, depression, or stress; the visual symptoms may serve as an unconscious coping mechanism for underlying psychological distress or trauma.<xref ref-type="bibr" rid="article-158117.r16">[16]</xref> In this sense, NOVL could be viewed as a form of conversion disorder, where psychological stress manifests as a physical symptom.<xref ref-type="bibr" rid="article-158117.r17">[17]</xref> At a neurophysiological level, the pathophysiology of NOVL may involve altered processing of visual information, leading to decoupled visual stimuli and conscious perception.<xref ref-type="bibr" rid="article-158117.r18">[18]</xref>&#x000a0;Early adverse experiences can potentially negatively affect the processing and interpretation of visual stimuli and manifest as vision loss.<xref ref-type="bibr" rid="article-158117.r14">[14]</xref></p>
        <p>Some patients with NOVL have normal visual acuity but report symptoms such as tunnel vision or photophobia.<xref ref-type="bibr" rid="article-158117.r19">[19]</xref> Other patients report dramatic vision loss but have normal responses to objective tests of visual function, like electroretinography or visual evoked potentials.<xref ref-type="bibr" rid="article-158117.r20">[20]</xref><xref ref-type="bibr" rid="article-158117.r21">[21]</xref>&#x000a0;&#x000a0;</p>
        <p>Malingering&#x000a0;comprises a portion of cases of NOVL. Here, the pathophysiology is rooted in a conscious decision to feign visual impairment. The motivations behind malingering vary widely and can include gaining financial benefits, evading responsibilities, or seeking attention.<xref ref-type="bibr" rid="article-158117.r22">[22]</xref></p>
        <p>Children are suggestible and often have a limited understanding of health and wellness. Some children misinterpret or exaggerate their visual symptoms due to confusion or fear, leading to discordance of self-reported vision loss and objective measures of visual function. The process of learning to read or dealing with school-related stress can sometimes trigger psychogenic visual symptoms.<xref ref-type="bibr" rid="article-158117.r23">[23]</xref></p>
      </sec>
      <sec id="article-158117.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>History</bold>
</p>
        <p>The presentation of&#x000a0;NOVL varies widely. The history of the present illness of patients with NOVL may be notable for inconsistencies and fluctuations in reported symptoms.</p>
        <p>Obtaining a comprehensive history is crucial when NOVL is suspected. It is essential to document the onset, duration, and progression of the reported visual symptoms, including visual complaints, such as blindness, or ocular findings, such as ptosis or blepharospasm.<xref ref-type="bibr" rid="article-158117.r17">[17]</xref>&#x000a0;Any sudden or inexplicable changes in vision or visual fields should be noted. Exacerbating or alleviating factors and associated symptoms such as headache, eye pain, or systemic symptoms should be queried.&#x000a0;</p>
        <p>Patients with NOVL frequently report vision loss or disturbances that do not conform to an anatomical or physiological pattern. Patients may report complete vision loss in one eye but have no difficulty navigating or sudden severe vision loss with a normal ophthalmoscopic examination.&#x000a0;Patients with NOVL&#x000a0;may&#x000a0;describe visual disturbances with unusual characteristics, such as "grey-out" or "white-out" episodes, which are not typically associated with organic visual disorders.<xref ref-type="bibr" rid="article-158117.r17">[17]</xref></p>
        <p>The personal past ocular and medical history should be thoroughly reviewed, with particular attention to previous eye conditions, surgeries, or trauma, and systemic conditions that might affect vision, such as diabetes or neurological disorders. The psychosocial history can provide valuable clues in patients with NOVL. Occupation, hobbies, home life, and recent stressors can be particularly revealing.<xref ref-type="bibr" rid="article-158117.r13">[13]</xref>&#x000a0;Personal gains associated with vision loss, such as litigation or disability benefits, should be considered.&#x000a0;The presence of psychiatric disorders such as anxiety or depression should be documented.&#x000a0;</p>
        <p>It is essential to perform a thorough medication review; many medications can cause vision changes. This review should include prescribed medications, over-the-counter pharmaceuticals, herbs, supplements, and recreational substances.<xref ref-type="bibr" rid="article-158117.r24">[24]</xref><xref ref-type="bibr" rid="article-158117.r25">[25]</xref></p>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>A thorough physical examination should be performed. A complete eye examination is necessary, including assessment of visual acuity, refraction, color vision, visual fields, ocular motility, pupillary responses, and stereopsis. Examination of the anterior and posterior segments of the eye&#x000a0;and intraocular pressure measurement is required.</p>
        <p>The physical examination of patients with NOVL is typically normal. Vision testing often yields normal or near-normal results when not reliant on patient subjective responses; patients may claim they cannot see the chart for formal visual acuity testing but have no problem identifying objects or navigating around the room. The pupils will react normally, and ocular motility will be full.&#x000a0;Ophthalmoscopic&#x000a0;and slit-lamp examinations&#x000a0;typically reveal no abnormalities.</p>
      </sec>
      <sec id="article-158117.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The evaluation of NOVL primarily relies on the medical history and comprehensive eye examination. However, further objective evaluation may be needed to confirm the diagnosis and exclude coexisting organic pathologies.</p>
        <p>
<bold>Examination Techniques</bold>
</p>
        <p>Numerous examination techniques that exploit the automatic or unconscious nature of specific visual responses that are difficult for a person to control or suppress are beneficial when evaluating patients with suspected NOVL. These techniques include but are not limited to observing patients when they are unaware of being observed, the optokinetic drum or strip, confrontation of visual fields, variable visual acuity testing, stereopsis testing, color testing, and the mirror test.&#x000a0;These tests should be performed in a supportive and nonaccusatory manner,&#x000a0;remembering that many patients with NOVL are not intentionally producing their symptoms and may be dealing with underlying psychological stressors that require appropriate care and treatment. The key to diagnosing NOVL&#x000a0;is recognizing inconsistencies in the history and physical examination and discriminating&#x000a0;NOVL from potential organic causes of vision loss.</p>
        <p>
<bold>Observing Unaware Patients</bold>
</p>
        <p>Observing behavior when patients believe they are alone or unobserved can sometimes yield helpful information. Patients claiming total vision loss who navigate around objects in the room, read, or perform other visually guided tasks without difficulty could have NOVL.</p>
        <p>
<bold>Optokinetic Drum or Strip</bold>
</p>
        <p>The optokinetic drum or strip is a tool that can induce optokinetic nystagmus, an involuntary eye movement that occurs as the eyes track moving objects or patterns.<xref ref-type="bibr" rid="article-158117.r26">[26]</xref>&#x000a0;The optokinetic response is difficult to suppress consciously and can demonstrate preserved vision in patients claiming significant or total vision loss. The&#x000a0;patient is asked to observe a rotating drum or moving strip with alternating black and white stripes during this test. Optokinetic nystagmus indicates that the patient can see the movement, even if they deny being able to do so.<xref ref-type="bibr" rid="article-158117.r27">[27]</xref></p>
        <p>
<bold>Confrontational Visual Field Testing</bold>
</p>
        <p>During confrontation visual field testing, the examiner compares their visual fields with those of the&#x000a0;patient. The examiner can perform this test by wiggling their fingers and asking the patient to report when they see fingers wiggling in different parts of their visual field. Patients with NOVL may demonstrate a tubular or "gun barrel" field, only identifying targets presented directly in front of them, or results may be inconsistent.<xref ref-type="bibr" rid="article-158117.r28">[28]</xref>&#x000a0;A tubular field is when the patient identifies the edge of the visual field at a fixed distance from the visual axis, regardless of the distance at which the target is presented. This also can be described as tunnel vision, in which the tunnel remains at a fixed diameter. A normal visual field, or a restricted field&#x000a0;caused by an organic process, should expand in size as the target shown is moved away from the observer.<xref ref-type="bibr" rid="article-158117.r29">[29]</xref></p>
        <p>
<bold>Variable Visual Acuity Testing</bold>
</p>
        <p>Manipulating the vision chart can sometimes reveal NOVL. Variations of misdirection may yield valuable information. Alternatively, occluding one eye and presenting the chart upside down or sideways can often lead to better-than-expected results as the patient may not realize they should be unable to read the chart in these orientations.<xref ref-type="bibr" rid="article-158117.r8">[8]</xref><xref ref-type="bibr" rid="article-158117.r30">[30]</xref></p>
        <p>
<bold>Stereopsis Testing</bold>
</p>
        <p>Stereopsis is the perception of depth and three-dimensional structure obtained based on visual information derived from two eyes by individuals with normally developed binocular vision.<xref ref-type="bibr" rid="article-158117.r31">[31]</xref>&#x000a0;Patients reporting monocular vision loss who pass a stereopsis test that requires input from both eyes may&#x000a0;have NOVL.</p>
        <p>
<bold>Color Testing</bold>
</p>
        <p>Red light testing, or the red desaturation test, is useful in assessing NOVL. During this test, the patient is asked to compare the brightness of a red light between both eyes. In organic pathologies, such as optic neuritis or severe glaucoma, the affected eye will perceive red light as less bright or saturated than the unaffected eye.<xref ref-type="bibr" rid="article-158117.r32">[32]</xref><xref ref-type="bibr" rid="article-158117.r33">[33]</xref>&#x000a0;However, in NOVL, where the visual loss or impairment has no organic or physical cause, the perception of red light is usually equal in both eyes. Color testing relies on the principle that color vision, particularly red vision, is preserved until late in the course of organic eye diseases; discrepancies in reporting can suggest a nonorganic etiology.<xref ref-type="bibr" rid="article-158117.r33">[33]</xref>&#x000a0;This simple test should be used with other clinical findings and tests to establish a diagnosis. Ishihara color plates may be used for a more formal evaluation of color vision, but the red desaturation test is a quick test that does not require specialized equipment.<xref ref-type="bibr" rid="article-158117.r34">[34]</xref></p>
        <p>
<bold>Mirror Test</bold>
</p>
        <p>In the mirror test, a mirror reflects the image of an eye chart or other visual target into the eye that the patient claims is blind. The mirror is held on the side of the "good" eye, and if the patient can identify the chart or target, it indicates that the "bad" eye has functional vision.</p>
        <p>
<bold>Laboratory Tests</bold>
</p>
        <p>While there are no specific laboratory tests for NOVL, it may be necessary to order tests if an underlying physical or psychiatric condition is suspected. The choice of these tests depends on the&#x000a0;specific presentation and may include a complete blood count, thyroid function tests, or tests for autoimmune conditions.&#x000a0;</p>
        <p>
<bold>Imaging</bold>
</p>
        <p>Radiographic imaging, such as magnetic resonance imaging or computed tomography, may be required to exclude organic pathologies, particularly in cases suggestive of neurological disease or inconsistent findings.&#x000a0;These studies will typically reveal no abnormalities in patients with NOVL.</p>
        <p>
<bold>Optical Coherence Tomography</bold>
</p>
        <p>Optical coherence tomography can help corroborate the diagnosis of NOVL by demonstrating normal retinal and optic nerve anatomy in the face of reported visual loss.<xref ref-type="bibr" rid="article-158117.r35">[35]</xref></p>
        <p>
<bold>Electrodiagnostic Testing</bold>
</p>
        <p>Electrophysiological tests such as electroretinography and visually evoked potential may be employed to exclude retinal and optic nerve diseases, respectively. These tests typically reveal no abnormalities in patients with NOVL.<xref ref-type="bibr" rid="article-158117.r20">[20]</xref><xref ref-type="bibr" rid="article-158117.r21">[21]</xref></p>
        <p>
<bold>Psychological Evaluation</bold>
</p>
        <p>A psychological evaluation is often beneficial because of the strong link between NOVL and psychological factors. Mental health professionals can identify stressors or psychiatric conditions, such as depression or anxiety, that may be contributing to symptoms.<xref ref-type="bibr" rid="article-158117.r36">[36]</xref></p>
      </sec>
      <sec id="article-158117.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Effectively managing NOVL requires balancing reassurance, therapy, and referral when necessary. An essential component of managing NOVL is the physician-patient relationship, where trust and understanding are vital, and empathy and patience are paramount. Treating NOVL may be a prolonged process. Patients with NOVL may seek multiple opinions from clinicians. Surgical intervention is not required unless a coincident organic pathology is present.</p>
        <p>
<bold>Reassurance and Education</bold>
</p>
        <p>One of the mainstays of treatment in NOVL is patient reassurance. This is often the most challenging yet crucial part of the treatment, requiring delicacy and tact to communicate the diagnosis. The clinician should explain to the patient that their eyes and visual pathways function normally; no organic disease is present, but their symptoms are real. Educating patients about potential causes, such as stress or psychological factors, is beneficial.<xref ref-type="bibr" rid="article-158117.r37">[37]</xref></p>
        <p>
<bold>Referral to Mental and Behavioral Health Professionals</bold>
</p>
        <p>Referral to a psychologist or psychiatrist for further evaluation and management can be crucial to improving the quality of life in patients with NOVL. Cognitive-behavioral therapy may be beneficial. A mental health professional can help patients cope with contributing stressors or underlying psychiatric conditions.<xref ref-type="bibr" rid="article-158117.r38">[38]</xref></p>
        <p>
<bold>Continuity of Care</bold>
</p>
        <p>Patients with NOVL require frequent monitoring; the treatment plan should be adjusted as needed. The specific situation and clinical judgment of the healthcare provider dictate the timing of clinic visits.<xref ref-type="bibr" rid="article-158117.r38">[38]</xref></p>
      </sec>
      <sec id="article-158117.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>By definition, NOVL lacks causative identifiable organic pathology. However, organic causes of visual disturbances must be excluded before diagnosing NOVL.&#x000a0;</p>
        <p>
<bold>Commonly Encountered Organic Ocular Diseases</bold>
</p>
        <p>Cataracts, glaucoma, macular degeneration, retinal detachment, and optic neuritis&#x000a0;are common ocular diseases that may present with visual changes or vision loss. While the physical examination, imaging studies, or laboratory testing typically demonstrate identifiable abnormalities, early or mild cases may not.</p>
        <p>Some conditions may require more specialized diagnostic testing. For example, Stargardt disease, an inherited juvenile macular degeneration, often presents with vision loss during childhood or adolescence. Although certain signs may be present on ophthalmoscopic examination, such as yellow-white flecks at the level of the retinal pigment epithelium, these are not always apparent, especially in the early stages of the disease.<xref ref-type="bibr" rid="article-158117.r39">[39]</xref> The diagnosis often relies on fluorescein angiography, which can demonstrate characteristic dark choroid or "silent choroid" alongside other specific findings like perifoveal hyperfluorescence.<xref ref-type="bibr" rid="article-158117.r40">[40]</xref>&#x000a0;</p>
        <p>Advanced imaging may be required to diagnose an organic cause of vision loss&#x000a0;and avoid a misdiagnosis of NOVL. Neuro-ophthalmic conditions like optic neuritis or ischemic optic neuropathy may initially present with normal-appearing optic nerves or possess only retrobulbar findings.<xref ref-type="bibr" rid="article-158117.r41">[41]</xref><xref ref-type="bibr" rid="article-158117.r42">[42]</xref>&#x000a0;Retinitis pigmentosa may be subtle in the early stages of the disease.<xref ref-type="bibr" rid="article-158117.r43">[43]</xref>&#x000a0;Glaucoma can masquerade as&#x000a0;NOVL when it presents with normal intraocular pressure; this is normal-tension glaucoma.<xref ref-type="bibr" rid="article-158117.r44">[44]</xref> These cases underscore the importance of a detailed assessment and often specialized testing when considering a diagnosis of NOVL.&#x000a0;</p>
        <p>
<bold>Commonly Misdiagnosed Organic Ocular Diseases</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Big Blind Spot Syndrome: Also known as enlarged blind spot syndrome, this condition is marked by an idiopathic enlargement of the physiologic blind spot, commonly&#x000a0;associated with photopsia, scotomas, and visual field defects. The optic nerve typically appears normal, which may lead to a misdiagnosis of functional visual loss.<xref ref-type="bibr" rid="article-158117.r45">[45]</xref> The pathophysiology of this syndrome&#x000a0;is unclear, and treatment focuses on monitoring for the development of associated conditions, such as multiple evanescent white dot syndrome (MEWDS) or acute idiopathic blind spot enlargement (AIBSE).<xref ref-type="bibr" rid="article-158117.r46">[46]</xref><xref ref-type="bibr" rid="article-158117.r47">[47]</xref>&#x000a0;Big blind spot syndrome may also be a paraneoplastic phenomenon.<xref ref-type="bibr" rid="article-158117.r48">[48]</xref></p>
          </list-item>
          <list-item>
            <p>Acute Zonal Occult Outer Retinopathy: This process typically affects young, myopic women, presenting as acute photopsia and an enlarging scotoma. The retinal exam may reveal no abnormalities, but electrophysiologic testing often shows significant changes. Atrophic changes of the retinal pigment epithelium may develop, and visual field defects often stabilize but do not improve.<xref ref-type="bibr" rid="article-158117.r49">[49]</xref></p>
          </list-item>
          <list-item>
            <p>Bilateral Retrochiasmal Disease: Diseases affecting the occipital lobe, such as strokes or tumors, can cause homonymous visual field defects that may be mistaken for functional visual loss if misinterpreted by the patient or clinician. The key to this diagnosis is the congruity of visual field defects, which is higher in more posterior lesions.<xref ref-type="bibr" rid="article-158117.r50">[50]</xref><xref ref-type="bibr" rid="article-158117.r51">[51]</xref>&#x000a0;Neuroimaging is recommended and frequently required.<xref ref-type="bibr" rid="article-158117.r52">[52]</xref></p>
          </list-item>
          <list-item>
            <p>Chiasmal Disease without Optic Atrophy: Masses such as craniopharyngiomas or pituitary adenomas impinging on the optic chiasm can cause subtle bitemporal hemianopsia&#x000a0;that is easily overlooked. Detailed perimetry and neuroimaging are mandatory when a lesion is suspected.<xref ref-type="bibr" rid="article-158117.r53">[53]</xref></p>
          </list-item>
          <list-item>
            <p>Cone-Rod Dystrophy: These rare, hereditary disorders cause progressive vision loss due to the death of the retinal photoreceptive cone and rod cells. Photophobia, reduced central vision, color vision disturbances, and peripheral visual field loss are common.<xref ref-type="bibr" rid="article-158117.r54">[54]</xref></p>
          </list-item>
          <list-item>
            <p>Early Keratoconus or Irregular Astigmatism: These conditions cause irregular corneal curvature, distortion of vision, and ghosting. Visual acuity can often be corrected to 20/20 with glasses in the early stages. However, rigid contact lenses may improve vision complaints.<xref ref-type="bibr" rid="article-158117.r55">[55]</xref></p>
          </list-item>
          <list-item>
            <p>Early Posterior Subcapsular Cataracts: These cataracts are located in the back of the lens and often cause significant glare and decreased visual acuity in bright light. The cataract may be subtle and not visualized during routine slit-lamp examination. The brightness acuity test can help detect glare and is an important test for these cataracts.<xref ref-type="bibr" rid="article-158117.r56">[56]</xref></p>
          </list-item>
          <list-item>
            <p>Leber Hereditary Optic Neuropathy: This process causes subacute loss of central vision in young adults, predominantly men. The optic nerve may initially appear normal despite significant vision loss. Genetic testing is required for diagnosis.<xref ref-type="bibr" rid="article-158117.r57">[57]</xref></p>
          </list-item>
          <list-item>
            <p>Macular Changes:&#x000a0;Subtle central serous retinopathy, macular edema, and epiretinal membrane cause subtle macular changes and distort central vision. Optical coherence tomography may be required to confirm the diagnosis.<xref ref-type="bibr" rid="article-158117.r58">[58]</xref></p>
          </list-item>
          <list-item>
            <p>Paraneoplastic Retinopathy: These conditions, including cancer-associated retinopathy and melanoma-associated retinopathy, cause rapid, painless vision loss. Measurable autoantibodies associated with systemic malignancy attack the retina, causing significant damage.<xref ref-type="bibr" rid="article-158117.r59">[59]</xref></p>
          </list-item>
          <list-item>
            <p>Retinitis Pigmentosa Sine Pigmento: This variant of retinitis pigmentosa presents with night blindness and peripheral visual field loss but lacks the classic bone spicule pigmentation early in the disease. Electroretinogram testing is required for diagnosis.<xref ref-type="bibr" rid="article-158117.r60">[60]</xref></p>
          </list-item>
          <list-item>
            <p>Retrobulbar Optic Neuropathy: Often caused by demyelinating diseases such as multiple sclerosis, this condition affects the optic nerve behind the globe. Rapid vision loss, pain with eye movement, and an afferent pupillary defect can occur even while the optic nerve head appears normal.<xref ref-type="bibr" rid="article-158117.r61">[61]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Migraine Headaches</bold>
</p>
        <p>Visual disturbances occur frequently during a migrainous&#x000a0;episode and may be mistaken for NOVL. Patients with migraine headaches often describe their visual symptoms as transient, short-lived, and associated with headache, nausea, or sensitivity to light or sound; the duration of symptoms varies.<xref ref-type="bibr" rid="article-158117.r62">[62]</xref></p>
        <p>
<bold>Functional Neurological Disorder</bold>
</p>
        <p>Conversion disorder, also known as functional neurological symptom disorder, is a condition where patients present with physical neurological symptoms without an identifiable organic cause. Symptoms may include vision loss. Conversion disorder is believed to be a psychological response to stressful situations, trauma, or underlying mental health issues. The symptoms&#x000a0;are not intentionally produced&#x000a0;and may cause significant distress and impairment in social and occupational functioning.<xref ref-type="bibr" rid="article-158117.r63">[63]</xref></p>
        <p>
<bold>Somatic Symptom Disorder</bold>
</p>
        <p>Somatic symptom disorder is a psychiatric condition characterized by an excessive focus on physical symptoms that cause significant distress and interfere with daily functioning. Patients may present with a variety of physical complaints, including vision loss. The primary concern is not the presence or absence of a medical condition but the excessive reaction and health concerns in response to symptoms, which persist despite appropriate medical evaluation and reassurance.<xref ref-type="bibr" rid="article-158117.r64">[64]</xref></p>
        <p>
<bold>Malingering</bold>
</p>
        <p>Malingering is a condition characterized by the intentional production of false or grossly exaggerated physical or psychological symptoms. Individuals who are malingering are typically motivated by external incentives such as obtaining medication, avoiding work, evading criminal prosecution, or gaining other personal benefits. Malingering is not considered a psychiatric disorder but a deliberate attempt to deceive and manipulate others for personal gain.<xref ref-type="bibr" rid="article-158117.r12">[12]</xref>&#x000a0;</p>
        <p>Malingering with visual symptoms is still termed NOVL. In these cases, individuals consciously feign vision loss or exaggerate existing minor visual disturbances to achieve a particular external benefit. Unlike other forms of NOVL, patients with malingering are fully aware of their deception. Recognizing malingering is crucial in evaluating&#x000a0;NOVL as it helps avoid unnecessary medical procedures and interventions.</p>
      </sec>
      <sec id="article-158117.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for NOVL varies with the underlying cause. With proper identification and management of the cause, most patients with NOVL experience significant improvement or complete resolution of their symptoms.<xref ref-type="bibr" rid="article-158117.r37">[37]</xref>&#x000a0;The prognosis also depends on timely and accurate diagnosis, close monitoring, and personalized treatment planning.<xref ref-type="bibr" rid="article-158117.r65">[65]</xref>&#x000a0;</p>
        <p>In patients with functional vision loss related to conversion disorder or somatic symptom disorder, the prognosis is generally favorable with psychological intervention.<xref ref-type="bibr" rid="article-158117.r17">[17]</xref> These individuals often improve considerably&#x000a0;when the treatment approach incorporates cognitive-behavioral therapy techniques. Developing a strong therapeutic alliance between the healthcare provider and the patient significantly improves the outcome.<xref ref-type="bibr" rid="article-158117.r6">[6]</xref></p>
        <p>In cases of malingering, the prognosis for the visual disturbance itself is inherently good since the deficit is not due to underlying ocular pathology. However, addressing the driving factors behind malingering can be challenging and may require a multifaceted approach involving mental health professionals, social workers, or law enforcement.<xref ref-type="bibr" rid="article-158117.r22">[22]</xref></p>
        <p>NOVL in children secondary to stressors or attention-seeking behaviors&#x000a0;often improves when the underlying issue is identified and addressed. In many cases, reassurance and time are significant factors in the resolution of symptoms.<xref ref-type="bibr" rid="article-158117.r14">[14]</xref></p>
      </sec>
      <sec id="article-158117.s10" sec-type="Complications">
        <title>Complications</title>
        <p>NOVL does not cause direct physical harm; it can have significant effects on mental health, daily functioning, and quality of life.&#x000a0;Patients with NOVL often experience a high degree of anxiety, frustration, and distress&#x000a0;that exacerbates preexisting mental health conditions and may lead to the development of depressive symptoms or anxiety disorders.<xref ref-type="bibr" rid="article-158117.r66">[66]</xref>&#x000a0;Individuals with NOVL may face challenges in carrying out their daily activities, such as reading, driving, or walking. This can result in a reduced quality of life and increased dependence on others for assistance.<xref ref-type="bibr" rid="article-158117.r3">[3]</xref>&#x000a0;Stigmatization and misunderstanding by others can further add to their distress and isolation.</p>
        <p>If the nonorganic nature of the vision loss is not recognized early, multiple consultations, invasive investigations, and unnecessary treatments may ensue, leading to undue physical, psychological, and financial burdens to the patient.<xref ref-type="bibr" rid="article-158117.r67">[67]</xref>&#x000a0;Contrarily, focusing on nonorganic symptoms might overshadow a concurrent organic pathology, delaying appropriate diagnosis and treatment and leading to potentially avoidable vision loss or progression of the underlying organic condition.</p>
      </sec>
      <sec id="article-158117.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>NOVL stems from psychogenic or functional elements; a careful, comprehensive, patient-centered, and empathetic approach is crucial&#x000a0;when educating patients about their condition. The initial stage of patient education requires an empathetic, understanding, and nonjudgmental approach&#x000a0;to facilitate communication,&#x000a0;establish trust, and prevent the formation of conversational barriers. Alleviation of feelings of guilt or self-doubt minimizes conflict and distrust.<xref ref-type="bibr" rid="article-158117.r37">[37]</xref>&#x000a0;Accusatory language can harm the therapeutic relationship and impede progress.<xref ref-type="bibr" rid="article-158117.r3">[3]</xref></p>
        <p>A straightforward but sensitive explanation of the nature of NOVL should convey the underlying disconnect between normal visual pathways and disturbances in the interpretation of visual stimuli.&#x000a0;This explanation should underline that NOVL is not always a case of malingering or an attempt to deceive. Patients should be reassured about the generally favorable prognosis of NOVL and that full recovery is possible.<xref ref-type="bibr" rid="article-158117.r37">[37]</xref></p>
        <p>Clinicians should attempt to identify potential psychological or environmental triggers contributing to NOVL. Acknowledging these triggers may help with self-management.<xref ref-type="bibr" rid="article-158117.r6">[6]</xref>&#x000a0;Clinicians should be&#x000a0;forthcoming about the associations between NOVL and stress, anxiety, depression, somatic symptom disorder, or conversion disorder. Patients should be encouraged to engage in professional mental health support to help them understand the mind-body connection and how psychological distress can manifest as physical symptoms, including vision loss.<xref ref-type="bibr" rid="article-158117.r3">[3]</xref>&#x000a0;Therapies such as cognitive-behavioral therapy, mindfulness techniques, or counseling can be beneficial and&#x000a0;equip patients with tools and strategies to manage stress and anxiety that may be contributing to their symptoms.<xref ref-type="bibr" rid="article-158117.r37">[37]</xref>&#x000a0;Encouraging patients to adopt healthy lifestyle habits such as regular exercise, a balanced diet, and sufficient sleep can promote mental health and overall well-being.</p>
        <p>Regular clinic appointments allow for monitoring and signal to the patient that their symptoms and concerns are being taken seriously. Patients with malingering-associated NOVL may be unwilling to engage in ongoing care. However, patients with NOVL&#x000a0;secondary to conversion disorder are likely to return as they are genuinely interested in finding out what has caused their vision loss.<xref ref-type="bibr" rid="article-158117.r5">[5]</xref></p>
      </sec>
      <sec id="article-158117.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing&#x000a0;NOVL requires a comprehensive and collaborative interprofessional approach to enhance patient-centered care, improve outcomes, and ensure optimal team performance. Clear, respectful, and timely communication among all members of the healthcare team, including the primary care practitioner, ophthalmologist, optometrist, ophthalmic electrophysiologist, psychologist, psychiatrist, and nursing staff, is essential for coordinating efforts and effectively addressing the multifaceted nature of NOVL.&#x000a0;NOVL can be a distressing condition, and all healthcare providers need to maintain a compassionate, understanding, and nonjudgmental attitude to foster a therapeutic relationship.</p>
        <p>The complex underlying causes of NOVL range from physiological to psychological; diagnostic procedures require a comprehensive approach that considers input from various healthcare professionals. While the ophthalmologist or optometrist focuses on conducting a thorough eye examination to rule out organic causes of vision loss, mental health professionals, such as psychologists or psychiatrists, play a crucial role in investigating potential psychological triggers or conditions contributing to the patient's symptoms.</p>
        <p>Once the diagnosis of NOVL is established, it is essential for the healthcare team to collaboratively develop a tailored treatment plan that addresses both the visual symptoms and any underlying psychological factors. The process may encompass reassurance and education from the eyecare provider, counseling or psychotherapy from a mental health professional, and ongoing monitoring and support from the primary care practitioner and nursing staff.</p>
      </sec>
      <sec id="article-158117.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=158117&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=158117">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/nonorganic-vision-loss/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=158117">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/158117/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=158117">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-158117.s14">
        <title>References</title>
        <ref id="article-158117.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Broderick</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Ableman</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Enzenauer</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Wain</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Wroblewski</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Non-organic Vision Loss in the Afghanistan and Iraq Conflicts.</article-title>
            <source>Neuroophthalmology</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>175</fpage>
            <page-range>175-181</page-range>
            <pub-id pub-id-type="pmid">29344055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murcia-Belmonte</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Erskine</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Wiring the Binocular Visual Pathways.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Jul</month>
            <day>04</day>
            <volume>20</volume>
            <issue>13</issue>
            <pub-id pub-id-type="pmid">31277365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raviskanthan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wendt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ugoh</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Mortensen</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Functional vision disorders in adults: a paradigm and nomenclature shift for ophthalmology.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2022</year>
            <season>Jan-Feb</season>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-18</page-range>
            <pub-id pub-id-type="pmid">33737039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edwards</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Yogarajah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Author Correction: Why functional neurological disorder is not feigning or malingering.</article-title>
            <source>Nat Rev Neurol</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>384</fpage>
            <pub-id pub-id-type="pmid">37193749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Karagiannis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Crompton</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Selva</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Practical clinical approaches to functional visual loss.</article-title>
            <source>J Clin Neurosci</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-7</page-range>
            <pub-id pub-id-type="pmid">16730991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharpe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cavanagh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Butcher</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Duncan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Guided self-help for functional (psychogenic) symptoms: a randomized controlled efficacy trial.</article-title>
            <source>Neurology</source>
            <year>2011</year>
            <month>Aug</month>
            <day>09</day>
            <volume>77</volume>
            <issue>6</issue>
            <fpage>564</fpage>
            <page-range>564-72</page-range>
            <pub-id pub-id-type="pmid">21795652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daniel</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Coughtrey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heyman</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dahlmann-Noor</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Medically unexplained visual loss in children and young people: an observational single site study of incidence and outcomes.</article-title>
            <source>Eye (Lond)</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>31</volume>
            <issue>7</issue>
            <fpage>1068</fpage>
            <page-range>1068-1073</page-range>
            <pub-id pub-id-type="pmid">28282066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mursch-Edlmayr</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Mojon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bolz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Testing and approach when non-organic visual loss is suspected].</article-title>
            <source>Ophthalmologe</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>115</volume>
            <issue>1</issue>
            <fpage>77</fpage>
            <page-range>77-87</page-range>
            <pub-id pub-id-type="pmid">29273864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Impelen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Merckelbach</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jelicic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Niesten</surname>
                <given-names>IJM</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>J&#x000c0;</given-names>
              </name>
            </person-group>
            <article-title>Differentiating Factitious from Malingered Symptomatology: the Development of a Psychometric Approach.</article-title>
            <source>Psychol Inj Law</source>
            <year>2017</year>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>341</fpage>
            <page-range>341-357</page-range>
            <pub-id pub-id-type="pmid">29299086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duddu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Isaac</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Chaturvedi</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Somatization, somatosensory amplification, attribution styles and illness behaviour: a review.</article-title>
            <source>Int Rev Psychiatry</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-33</page-range>
            <pub-id pub-id-type="pmid">16451877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000f6;teles</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Witth&#x000f6;ft</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Somatosensory amplification - An old construct from a new perspective.</article-title>
            <source>J Psychosom Res</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>101</volume>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">28867412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bass</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wade</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Malingering and factitious disorder.</article-title>
            <source>Pract Neurol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>96</fpage>
            <page-range>96-105</page-range>
            <pub-id pub-id-type="pmid">30425128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takahashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kunikata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kawakami</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakazawa</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Familial Background Factors And Their Association With Non-Organic Visual Loss.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2019</year>
            <volume>13</volume>
            <fpage>2059</fpage>
            <page-range>2059-2061</page-range>
            <pub-id pub-id-type="pmid">31695319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Somers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Casteels</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Van Roie</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Spileers</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Casteels</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Non-organic visual loss in children: prospective and retrospective analysis of associated psychosocial problems and stress factors.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>94</volume>
            <issue>5</issue>
            <fpage>e312</fpage>
            <page-range>e312-6</page-range>
            <pub-id pub-id-type="pmid">26581506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scarpina</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Melzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Castelnuovo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mauro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marzoli</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Molinari</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Explicit and Implicit Components of the Emotional Processing in Non-organic Vision Loss: Behavioral Evidence About the Role of Fear in Functional Blindness.</article-title>
            <source>Front Psychol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>494</fpage>
            <pub-id pub-id-type="pmid">29692751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bennett</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hoeritzauer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gardiner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McWhirter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A practical review of functional neurological disorder (FND) for the general physician.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-36</page-range>
            <pub-id pub-id-type="pmid">33479065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Egan</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>LaFrance</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>Functional Vision Disorder.</article-title>
            <source>Semin Neurol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>557</fpage>
            <page-range>557-63</page-range>
            <pub-id pub-id-type="pmid">26444401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hallett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aybek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dworetzky</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>McWhirter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Staab</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Functional neurological disorder: new subtypes and shared mechanisms.</article-title>
            <source>Lancet Neurol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>537</fpage>
            <page-range>537-550</page-range>
            <pub-id pub-id-type="pmid">35430029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhanji</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lawlor</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Functional visual loss.</article-title>
            <source>Curr Opin Neurol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>200</fpage>
            <page-range>200-205</page-range>
            <pub-id pub-id-type="pmid">28141741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamilton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heinrich</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Odom</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>McCulloch</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>VEP estimation of visual acuity: a systematic review.</article-title>
            <source>Doc Ophthalmol</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>142</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-74</page-range>
            <pub-id pub-id-type="pmid">32488810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McBain</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Robson</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Hogg</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Holder</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Assessment of patients with suspected non-organic visual loss using pattern appearance visual evoked potentials.</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>245</volume>
            <issue>4</issue>
            <fpage>502</fpage>
            <page-range>502-10</page-range>
            <pub-id pub-id-type="pmid">17111152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orr&#x000f9;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ordali</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Monaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scarpazza</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Conversano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pietrini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gemignani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sartori</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Reconstructing individual responses to direct questions: a new method for reconstructing malingered responses.</article-title>
            <source>Front Psychol</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1093854</fpage>
            <pub-id pub-id-type="pmid">37397336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grattan-Smith</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Dale</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Pediatric functional neurologic symptoms.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2016</year>
            <volume>139</volume>
            <fpage>489</fpage>
            <page-range>489-498</page-range>
            <pub-id pub-id-type="pmid">27719866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mechrgui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kanani</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The Ophthalmic Side Effects of Topiramate: A Review.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>8</issue>
            <fpage>e28513</fpage>
            <pub-id pub-id-type="pmid">36059357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hui</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Common systemic medications that every optometrist should know.</article-title>
            <source>Clin Exp Optom</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>105</volume>
            <issue>2</issue>
            <fpage>149</fpage>
            <page-range>149-156</page-range>
            <pub-id pub-id-type="pmid">34407728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwarzbach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schwartze</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>[Induction of optokinetic nystagmus in infants and young children by a horizontally, diagonally or vertically moving striped pattern].</article-title>
            <source>Padiatr Grenzgeb</source>
            <year>1991</year>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>167</fpage>
            <page-range>167-82</page-range>
            <pub-id pub-id-type="pmid">2067867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robinson</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Neurophysiology of the optokinetic system.</article-title>
            <source>Prog Brain Res</source>
            <year>2022</year>
            <volume>267</volume>
            <issue>1</issue>
            <fpage>251</fpage>
            <page-range>251-269</page-range>
            <pub-id pub-id-type="pmid">35074057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Shuey</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Wall</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Rapid confrontation screening for peripheral visual field defects and extinction.</article-title>
            <source>Clin Exp Optom</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>92</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-8</page-range>
            <pub-id pub-id-type="pmid">19125747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fris&#x000e9;n</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Identification of functional visual field loss by automated static perimetry.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>92</volume>
            <issue>8</issue>
            <fpage>805</fpage>
            <page-range>805-9</page-range>
            <pub-id pub-id-type="pmid">24698019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levy</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>McCulley</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Feuer</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Estimating visual acuity by character counting using the Snellen visual acuity chart.</article-title>
            <source>Eye (Lond)</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>622</fpage>
            <page-range>622-4</page-range>
            <pub-id pub-id-type="pmid">15184944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Connor</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Tidbury</surname>
                <given-names>LP</given-names>
              </name>
            </person-group>
            <article-title>Stereopsis: are we assessing it in enough depth?</article-title>
            <source>Clin Exp Optom</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>101</volume>
            <issue>4</issue>
            <fpage>485</fpage>
            <page-range>485-494</page-range>
            <pub-id pub-id-type="pmid">29377291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fanlo Zarazaga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez V&#x000e1;squez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pueyo Royo</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Review of the main colour vision clinical assessment tests.</article-title>
            <source>Arch Soc Esp Oftalmol (Engl Ed)</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>94</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-32</page-range>
            <pub-id pub-id-type="pmid">30361001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bennett</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Costello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Petzold</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Biousse</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Galetta</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment.</article-title>
            <source>Lancet Neurol</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>89</fpage>
            <page-range>89-100</page-range>
            <pub-id pub-id-type="pmid">36155661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Somers</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Bosten</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Screening for mild anomalous trichromacy using the Ishihara plates test.</article-title>
            <source>J Opt Soc Am A Opt Image Sci Vis</source>
            <year>2023</year>
            <month>Mar</month>
            <day>01</day>
            <volume>40</volume>
            <issue>3</issue>
            <fpage>A208</fpage>
            <page-range>A208-A219</page-range>
            <pub-id pub-id-type="pmid">37133039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Invernizzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cozzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Staurenghi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Optical coherence tomography and optical coherence tomography angiography in uveitis: A review.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>357</fpage>
            <page-range>357-371</page-range>
            <pub-id pub-id-type="pmid">30719788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Onofrj</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ajdinaj</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Digiovanni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malek</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Martinotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ferro</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sensi</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Functional Neurologic Disorders, disorders to be managed by neurologists, or are neurologists wandering in a dangerous field with inadequate resources?</article-title>
            <source>Front Psychiatry</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1120981</fpage>
            <pub-id pub-id-type="pmid">37009111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phansalkar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lockman</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Bansal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>Management of Functional Vision Disorders.</article-title>
            <source>Curr Neurol Neurosci Rep</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>265</fpage>
            <page-range>265-273</page-range>
            <pub-id pub-id-type="pmid">35320465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilmour</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Teodoro</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yogarajah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coebergh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dilley</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Martino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Management of functional neurological disorder.</article-title>
            <source>J Neurol</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>267</volume>
            <issue>7</issue>
            <fpage>2164</fpage>
            <page-range>2164-2172</page-range>
            <pub-id pub-id-type="pmid">32193596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ricca</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Sohn</surname>
                <given-names>EH</given-names>
              </name>
            </person-group>
            <article-title>Stargardt disease masquerades.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>214</fpage>
            <page-range>214-224</page-range>
            <pub-id pub-id-type="pmid">33653979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Stargardt Disease.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2018</year>
            <volume>1085</volume>
            <fpage>139</fpage>
            <page-range>139-151</page-range>
            <pub-id pub-id-type="pmid">30578500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petzold</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Abegg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alroughani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alshowaeir</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alvarenga</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Andris</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Asgari</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Battistella</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Behbehani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bikbov</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Biotti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Biousse</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Boschi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brazdil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brezhnev</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Calabresi</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Cordonnier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Costello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Cunha</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Daoudi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deschamps</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Seze</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Diem</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Etemadifar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Flores-Rivera</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Frederiksen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frohman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Frohman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tilikete</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Fujihara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>G&#x000e1;lvez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gouider</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gracia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Grigoriadis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Guajardo</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Habek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hawlina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Lapiscina</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Hooker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hor</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Howlett</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Huang-Link</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Idrissova</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Illes</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Jancic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jindahra</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Karussis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kerty</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lagr&#x000e8;ze</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Leocani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Liskova</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Maiga</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Marignier</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McGuigan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meira</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Merle</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Monteiro</surname>
                <given-names>MLR</given-names>
              </name>
              <name>
                <surname>Moodley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moura</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mustafa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakashima</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Noval</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oehninger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ogun</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Omoti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pandit</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rebolleda</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Reddel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rejdak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rejdak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rodriguez-Morales</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Rougier</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Sa</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sanchez-Dalmau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Saylor</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shatriah</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Siva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stiebel-Kalish</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Szatmary</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tenembaum</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Trufanov</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>van Pesch</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Wattjes</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Willoughby</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zakaria</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zvornicanin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Balcer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Plant</surname>
                <given-names>GT</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and classification of optic neuritis.</article-title>
            <source>Lancet Neurol</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>12</issue>
            <fpage>1120</fpage>
            <page-range>1120-1134</page-range>
            <pub-id pub-id-type="pmid">36179757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Margo</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Pathology of Ischemic Optic Neuropathy.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>141</volume>
            <issue>1</issue>
            <fpage>162</fpage>
            <page-range>162-166</page-range>
            <pub-id pub-id-type="pmid">28029908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Retinitis Pigmentosa: Progress in Molecular Pathology and Biotherapeutical Strategies.</article-title>
            <source>Int J Mol Sci</source>
            <year>2022</year>
            <month>Apr</month>
            <day>28</day>
            <volume>23</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">35563274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>DYL</given-names>
              </name>
              <name>
                <surname>Tham</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Normal-tension glaucoma: Current concepts and approaches-A review.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>247</fpage>
            <page-range>247-259</page-range>
            <pub-id pub-id-type="pmid">35040248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volpe</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lessell</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Acute idiopathic blind spot enlargement syndrome: a review of 27 new cases.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>119</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-63</page-range>
            <pub-id pub-id-type="pmid">11146727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamed</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Glaser</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Gass</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Schatz</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Protracted enlargement of the blind spot in multiple evanescent white dot syndrome.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1989</year>
            <month>Feb</month>
            <volume>107</volume>
            <issue>2</issue>
            <fpage>194</fpage>
            <page-range>194-8</page-range>
            <pub-id pub-id-type="pmid">2916972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newcomb</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Acute, idiopathic blind spot enlargement syndrome.</article-title>
            <source>Optom Vis Sci</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>77</volume>
            <issue>4</issue>
            <fpage>178</fpage>
            <page-range>178-87</page-range>
            <pub-id pub-id-type="pmid">10795800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volpe</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Retinal disease in neuro-ophthalmology: paraneoplastic retinopathy and the big blind spot syndrome.</article-title>
            <source>Semin Ophthalmol</source>
            <year>1995</year>
            <month>Sep</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>234</fpage>
            <page-range>234-41</page-range>
            <pub-id pub-id-type="pmid">10159748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Acute Zonal Occult Outer Retinopathy (AZOOR) and Related Diseases.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2018</year>
            <volume>1085</volume>
            <fpage>233</fpage>
            <page-range>233-237</page-range>
            <pub-id pub-id-type="pmid">30578522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pal</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Dubey</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dewan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Sudden-Onset Bilateral Blindness in a Young Girl Receiving Parenteral Nutrition: Case Report and Review of Literature.</article-title>
            <source>JPEN J Parenter Enteral Nutr</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>41</volume>
            <issue>7</issue>
            <fpage>1240</fpage>
            <page-range>1240-1244</page-range>
            <pub-id pub-id-type="pmid">26290495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Anton-Babinski syndrome in an old patient: a case report and literature review.</article-title>
            <source>Psychogeriatrics</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <page-range>58-61</page-range>
            <pub-id pub-id-type="pmid">25515048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pula</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Yuen</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Eyes and stroke: the visual aspects of cerebrovascular disease.</article-title>
            <source>Stroke Vasc Neurol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>210</fpage>
            <page-range>210-220</page-range>
            <pub-id pub-id-type="pmid">29507782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dermarkarian</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Kini</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Al Othman</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Neuro-Ophthalmic Manifestations of Intracranial Malignancies.</article-title>
            <source>J Neuroophthalmol</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>40</volume>
            <issue>3</issue>
            <fpage>e31</fpage>
            <page-range>e31-e48</page-range>
            <pub-id pub-id-type="pmid">32282510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Progressive Cone Dystrophy and Cone-Rod Dystrophy (XL, AD, and AR).</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2018</year>
            <volume>1085</volume>
            <fpage>53</fpage>
            <page-range>53-60</page-range>
            <pub-id pub-id-type="pmid">30578485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santodomingo-Rubido</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carracedo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Suzaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Villa-Collar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Wolffsohn</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Keratoconus: An updated review.</article-title>
            <source>Cont Lens Anterior Eye</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>101559</fpage>
            <pub-id pub-id-type="pmid">34991971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paz Filgueira</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Issolio</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Straylight and Visual Quality on Early Nuclear and Posterior Subcapsular Cataracts.</article-title>
            <source>Curr Eye Res</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>41</volume>
            <issue>9</issue>
            <fpage>1209</fpage>
            <page-range>1209-15</page-range>
            <pub-id pub-id-type="pmid">26766561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stramkauskait&#x00117;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Povilaityt&#x00117;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Glebauskien&#x00117;</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liutkevi&#x0010d;ien&#x00117;</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Clinical Overview of Leber Hereditary Optic Neuropathy.</article-title>
            <source>Acta Med Litu</source>
            <year>2022</year>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-18</page-range>
            <pub-id pub-id-type="pmid">36061944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dysli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>R&#x000fc;ckert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Munk</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Differentiation of Underlying Pathologies of Macular Edema Using Spectral Domain Optical Coherence Tomography (SD-OCT).</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2019</year>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>474</fpage>
            <page-range>474-483</page-range>
            <pub-id pub-id-type="pmid">31184556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rahimy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sarraf</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: evaluation and management.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2013</year>
            <season>Sep-Oct</season>
            <volume>58</volume>
            <issue>5</issue>
            <fpage>430</fpage>
            <page-range>430-58</page-range>
            <pub-id pub-id-type="pmid">23969019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>UC</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>RETINITIS PIGMENTOSA SINE PIGMENTO: Clinical Spectrum and Pigment Development.</article-title>
            <source>Retina</source>
            <year>2022</year>
            <month>Apr</month>
            <day>01</day>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>807</fpage>
            <page-range>807-815</page-range>
            <pub-id pub-id-type="pmid">34907125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaphiades</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kline</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>Optic neuritis.</article-title>
            <source>Compr Ophthalmol Update</source>
            <year>2007</year>
            <season>Mar-Apr</season>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>67</fpage>
            <page-range>67-75; discussion 77-8</page-range>
            <pub-id pub-id-type="pmid">17540123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiang</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Dumitrascu</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Chhabra</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Migraine with Visual aura and the Risk of Stroke- a Narrative Review.</article-title>
            <source>J Stroke Cerebrovasc Dis</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>30</volume>
            <issue>11</issue>
            <fpage>106067</fpage>
            <pub-id pub-id-type="pmid">34461446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feinstein</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Conversion Disorder.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>3, BEHAVIORAL NEUROLOGY AND PSYCHIATRY</issue>
            <fpage>861</fpage>
            <page-range>861-872</page-range>
            <pub-id pub-id-type="pmid">29851882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f6;we</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levenson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Depping</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>H&#x000fc;sing</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kohlmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lehmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shedden-Mora</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toussaint</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Uhlenbusch</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Weigel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Somatic symptom disorder: a scoping review on the empirical evidence of a new diagnosis.</article-title>
            <source>Psychol Med</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>632</fpage>
            <page-range>632-648</page-range>
            <pub-id pub-id-type="pmid">34776017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Genderen</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>de Wit</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Riemslag</surname>
                <given-names>FC</given-names>
              </name>
            </person-group>
            <article-title>[Functional vision disorder: timely examination pays off].</article-title>
            <source>Ned Tijdschr Geneeskd</source>
            <year>2016</year>
            <volume>160</volume>
            <fpage>A9656</fpage>
            <pub-id pub-id-type="pmid">27299486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aybek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of functional neurological disorder.</article-title>
            <source>BMJ</source>
            <year>2022</year>
            <month>Jan</month>
            <day>24</day>
            <volume>376</volume>
            <fpage>o64</fpage>
            <pub-id pub-id-type="pmid">35074803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158117.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Espay</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Aybek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Hallett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>LaFaver</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>LaFrance</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Nicholson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Reuber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Voon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morgante</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders.</article-title>
            <source>JAMA Neurol</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>75</volume>
            <issue>9</issue>
            <fpage>1132</fpage>
            <page-range>1132-1141</page-range>
            <pub-id pub-id-type="pmid">29868890</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
